Astellas Pharma Inc. Q3/FY2022 FINANCIAL RESULTS ENDED DECEMBER 31, 2022

Representative Director, President and CEO
Kenji Yasukawa
Representative Director, Executive Vice President, Chief Strategy Officer (CStO)
Naoki Okamura
Chief Financial Officer (CFO)
Minoru Kikuoka
Chief Commercial Officer (CCO)
Yukio Matsui
Chief Scientific Officer (CScO)
Yoshitsugu Shitaka
Chief Medical Officer (CMO)
Tadaaki Taniguchi

PLAY LIST

from the beginning

Q3/FY2022 FINANCIAL RESULTS ENDED DECEMBER 31, 2022

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Q3/FY2022 Consolidated Financial Results

Q3/FY2022 FINANCIAL RESULTS: OVERVIEW

Q3/FY2022 FINANCIAL RESULTS

Q3/FY2022 FINANCIAL RESULTS & OUTLOOK: XTANDI

Q3/FY2022 FINANCIAL RESULTS & OUTLOOK: STRATEGIC PRODUCTS

Q3/FY2022 FINANCIAL RESULTS: COST ITEMS

OUTLOOK FOR FY2022

Initiatives for Sustainable Growth

XTANDI & STRATEGIC PRODUCTS: KEY EVENTS EXPECTED IN FY2022

ZOLBETUXIMAB: LATEST STATUS

PROGRESS IN FOCUS AREA APPROACH (1/3): CURRENT STATUS OF PROJECTS IN CLINICAL TRIAL

PROGRESS IN FOCUS AREA APPROACH (2/3): CURRENT STATUS OF AT845 AND AT132

PROGRESS IN FOCUS AREA APPROACH (3/3): COLLABORATION WITH SELECTA BIOSCIENCES

PROGRESS TOWARD ACHIEVING CSP2021

UPCOMING EVENT

CHANGE EXCHANGE RATES USED FOR ELIMINATION OF UNREALIZED PROFIT ON INVENTORIES (PRO FORMA FIGURES)

Q3/FY2022: REVENUE BY REGION

Q3/FY2022: SALES OF MAIN PRODUCTS

Q3/FY2022 ACTUAL: FX RATE

FY2022 FCST: FX RATE & FX SENSITIVITY

BALANCE SHEET & CASH FLOW HIGHLIGHTS

CAPITAL ALLOCATION

ROBUST PIPELINE OF ASTELLAS

PROGRESS IN OVERALL PIPELINE

XTANDI & STRATEGIC PRODUCTS: STATUS UPDATE

ENZALUTAMIDE (1/2): ANDROGEN RECEPTOR INHIBITOR

ENZALUTAMIDE (2/2): PHASE 3 STUDY DATA BY DISEASE STAGE

ENFORTUMAB VEDOTIN (EV) (1/4): NECTIN-4 TARGETED ADC OVERALL UC PROGRAM

ENFORTUMAB VEDOTIN (EV) (2/4): CLINICAL STUDIES

ENFORTUMAB VEDOTIN (EV) (3/4): STUDY DATA BY DISEASE STAGE OF UC

ENFORTUMAB VEDOTIN (EV) (4/4): FUTURE OUTLOOK

GILTERITINIB: FLT3 INHIBITOR

ZOLBETUXIMAB: ANTI CLAUDIN 18.2 MONOCLONAL ANTIBODY

FEZOLINETANT: NK3 RECEPTOR ANTAGONIST

AT132 (RESAMIRIGENE BILPARVOVEC): rAAV8-Des-hMTM1

FOCUS AREA APPROACH: CLINICAL PROOF AND EXPANSION OF KEY PLATFORMS

ON THE FOREFRONT OF HEALTHCARE CHANGE

Questions 1

Questions 2

Questions 3

Questions 4

Questions 5

Questions 6

Questions 7

Questions 8

Back
Next

Download

Presentation File(PDF 642 KB)